Patents Represented by Attorney Michael G. Biro
-
Patent number: 7135555Abstract: The present invention provides isolated human and bovine TNF-? convertases, nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-?. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-? convertases, and for identifying nucleic acids encoding such convertases.Type: GrantFiled: May 14, 2002Date of Patent: November 14, 2006Assignee: Schering CorporationInventors: Barbara Dalie, Xuedong Fan, Daniel Lundell, Charles A. Lunn, Jimmy C. Tan, Paul J. Zavodny
-
Patent number: 6933107Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.Type: GrantFiled: May 15, 2003Date of Patent: August 23, 2005Assignee: Schering CorporationInventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Jr., Michael P. Graziano, Maureen Laverty, Xiaorui Yao
-
Patent number: 6923966Abstract: Methods for treating treatment-naive as well as treatment-experienced patients having melanoma to increase the progression-free survival time involving administering a therapeutically effective amount of pegylated interferon-alpha, e.g., preferably pegylated interferon alpha-2b, as adjuvant therapy to definitive surgery are disclosed.Type: GrantFiled: July 12, 2001Date of Patent: August 2, 2005Assignee: Schering CorporationInventors: Mary Ellen Rybak, Esther Helen Rose
-
Patent number: 6878528Abstract: Purified mammalian DC cell surface protein, designated Langerin, nucleic acids encoding Langerin, and antibodies which specifically bind Langerin.Type: GrantFiled: September 23, 1999Date of Patent: April 12, 2005Assignee: Schering CorporationInventors: Valerie Duvert-Frances, Jean-Jacques Pin, Jenny Valladeau, Valerie Clair, Sem Saeland, Serge J. E. Lebecque
-
Patent number: 6875580Abstract: The invention provides immunological reagents (antibodies) capable of binding to plasmacytoid dendritic cells (pDC), to cell lines which express such antibodies and to a process for identifying and purifying plasmacytoid dendriticcells from tissues containing pDC using such antibodies.Type: GrantFiled: January 26, 2004Date of Patent: April 5, 2005Assignee: Schering CorporationInventors: Carine Paturel, Giorgio Trinchieri, Jean-Jacques Pin
-
Patent number: 6812004Abstract: A novel CC chemokine which is from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said chemokine. Methods of using said reagents and diagnostic kits are also provided.Type: GrantFiled: February 10, 1997Date of Patent: November 2, 2004Assignee: Schering CorporationInventors: Christophe Caux, Serge J. E. Lebecque, Jacques Banchereau
-
Patent number: 6774214Abstract: Nucleic acids encoding various monocyte-derived proteins and related compositions, including purified proteins and specific antibodies are described. Methods of using such composition are also provided.Type: GrantFiled: October 9, 2001Date of Patent: August 10, 2004Assignee: Schering CorporationInventors: Elizabeth Bates, Nathalie Fournier, Lionel Chalus, Pierre Garrone
-
Patent number: 6762341Abstract: Compositions and methods for using mammalian CCR8 receptor proteins, antagonists and related reagents to treat diseases or conditions associated with Th2-mediated responses in an individual, especially asthma, are provided. The methods comprise administering a therapeutically effective amount of a CCR8 antagonist, alone or in combination with other therapeutic reagents. Also provided are methods for screening for therapeutics. Genetically-engineered animals and their use as models of molecular mechanism are also provided.Type: GrantFiled: February 9, 2001Date of Patent: July 13, 2004Assignee: Schering CorporationInventor: Sergio A. Lira
-
Patent number: 6756478Abstract: Nucleic acids encoding various lymphocyte cell proteins from mammalian, including primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.Type: GrantFiled: May 22, 2001Date of Patent: June 29, 2004Assignee: Schering CorporationInventors: Jenny Valladeau, Odile Ravel, Elizabeth Esther Mary Bates, John Ford, Sem Saeland, Serge J. E. Lebecque
-
Patent number: 6632933Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.Type: GrantFiled: July 30, 2001Date of Patent: October 14, 2003Assignee: Schering CorporationInventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Jr., Michael P. Graziano, Maureen Laverty, Xiaorui Yao
-
Patent number: 6613533Abstract: The present invention provides an isolated mammalian histamine receptor, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods of making the receptor using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptor and are useful for treating medical conditions caused or mediated by histamine. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian histamine receptor.Type: GrantFiled: March 19, 2001Date of Patent: September 2, 2003Assignee: Schering CorporationInventors: Jiang X. Behan, Joseph A. Hedrick, Thomas M. Laz, Frederick J. Monsma, Kelley L. Morse, Shelby P. Umland, Suke Wang
-
Patent number: 6610905Abstract: The present invention relates to a non-human transgenic mouse containing a constitutively active G-protein coupled receptor, which produces Kaposi's sarcoma-like symptoms. The transgenic mouse is useful in identification of reagents for the prevention, treatment and/or cure of diseases related to production of proliferative vascular lesions, including Kaposi's sarcoma.Type: GrantFiled: July 19, 2000Date of Patent: August 26, 2003Assignee: Schering CorporationInventors: Sergio A. Lira, Tong-Yuan Yang
-
Patent number: 6593078Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.Type: GrantFiled: April 12, 2000Date of Patent: July 15, 2003Assignee: Schering CorporationInventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Jr., Michael P. Graziano, Maureen Laverty, Xiaorui Yao
-
Patent number: 6531290Abstract: The present invention provides isolated human and bovine TNF-&agr; convertases, nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-&agr;. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-&agr; convertases, and for identifying nucleic acids encoding such convertases.Type: GrantFiled: October 17, 2001Date of Patent: March 11, 2003Assignee: Schering CorporationInventors: Barbara Dalie, Xuedong Fan, Daniel Lundell, Charles A. Lunn, Jimmy C. Tan, Paul J. Zavodny
-
Patent number: 6416954Abstract: The present invention relates to the agonist properties of vMIP-I for the chemokine receptor CCR8 as expressed on Th2 cells. Methods of modulating a physiological signal specific to Th2 cells comprising contacting these cells with vMIP-I, agonists and antagonists thereof are disclosed. Methods for treating disease using CCR8 antagonists are also provided. The modulation of the Th2 cell populations through the vMIP-I/CCR8 interaction provides a new means for diagnosing and treating specific disease states and immunologic conditions.Type: GrantFiled: February 3, 2000Date of Patent: July 9, 2002Assignee: Schering CorporationInventor: Joseph A. Hedrick